Capital Asset Advisory Services LLC Has $2.51 Million Stake in Pfizer Inc. (NYSE:PFE)

Capital Asset Advisory Services LLC increased its stake in shares of Pfizer Inc. (NYSE:PFE) by 6.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 94,312 shares of the biopharmaceutical company’s stock after buying an additional 5,632 shares during the quarter. Capital Asset Advisory Services LLC’s holdings in Pfizer were worth $2,508,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Blue Trust Inc. grew its holdings in shares of Pfizer by 14.9% during the 4th quarter. Blue Trust Inc. now owns 61,517 shares of the biopharmaceutical company’s stock worth $1,780,000 after purchasing an additional 7,958 shares in the last quarter. PFG Investments LLC lifted its position in Pfizer by 2.6% during the fourth quarter. PFG Investments LLC now owns 206,418 shares of the biopharmaceutical company’s stock worth $5,476,000 after purchasing an additional 5,157 shares during the period. Empirical Financial Services LLC d.b.a. Empirical Wealth Management grew its stake in Pfizer by 7.0% during the fourth quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 46,758 shares of the biopharmaceutical company’s stock worth $1,240,000 after buying an additional 3,078 shares in the last quarter. Regatta Capital Group LLC increased its holdings in Pfizer by 10.5% in the 4th quarter. Regatta Capital Group LLC now owns 15,594 shares of the biopharmaceutical company’s stock valued at $414,000 after buying an additional 1,480 shares during the period. Finally, Novare Capital Management LLC acquired a new position in shares of Pfizer in the 4th quarter valued at approximately $228,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Trading Down 1.3 %

Shares of PFE stock opened at $26.10 on Monday. The stock has a 50-day moving average of $26.11 and a 200-day moving average of $27.94. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The stock has a market cap of $147.89 billion, a price-to-earnings ratio of 35.27, a PEG ratio of 0.64 and a beta of 0.64. Pfizer Inc. has a 1-year low of $24.48 and a 1-year high of $31.54.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The firm had revenue of $17.70 billion for the quarter, compared to the consensus estimate of $14.92 billion. During the same quarter in the previous year, the company earned ($0.17) EPS. The company’s revenue for the quarter was up 31.2% on a year-over-year basis. On average, equities research analysts forecast that Pfizer Inc. will post 2.94 earnings per share for the current year.

Pfizer Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.59%. This is an increase from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date is Friday, January 24th. Pfizer’s payout ratio is currently 227.03%.

Insider Activity at Pfizer

In other news, Director Scott Gottlieb bought 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 30th. The stock was acquired at an average cost of $28.24 per share, with a total value of $28,240.00. Following the transaction, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $282,400. This represents a 11.11 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.06% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. Guggenheim decreased their price objective on shares of Pfizer from $35.00 to $33.00 and set a “buy” rating on the stock in a research note on Wednesday, December 11th. Wolfe Research initiated coverage on Pfizer in a report on Friday, November 15th. They set an “underperform” rating and a $25.00 price target for the company. Evercore ISI raised Pfizer to a “strong-buy” rating in a research note on Wednesday, October 30th. Citigroup assumed coverage on Pfizer in a research note on Friday, October 25th. They set a “neutral” rating and a $30.00 target price for the company. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research note on Wednesday, October 23rd. One research analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $32.00.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.